Singular Genomics Systems (OMIC)
(Real Time Quote from BATS)
$7.05 USD
0.00 (0.00%)
Updated Aug 8, 2024 10:02 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OMIC 7.05 0.00(0.00%)
Will OMIC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OMIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OMIC
Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates
Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates
OMIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Similar Genomics Systems (OMIC) Could be Great Choice for a Bottom Fisher
Other News for OMIC
Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024
Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Singular Genomics Systems trading resumes
Singular Genomics Systems trading halted, volatility trading pause
OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Misses Revenue for Q2 2023